Eli Lilly and Co
LLY
Company Profile
Business description
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Contact
Lilly Corporate Center
IndianapolisIN46285
USAT: +1 317 276-2000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
47,000
Stocks News & Analysis
stocks
The ultimate investing hack: dividend growth stocks
Finding companies built for lasting dividend growth.
stocks
Is the data centre party over for Goodman?
Global spending spree on data centres could mean a declining return on invested capital.
stocks
Is AUB an opportunity after shares plunge 17%?
After a takeover bid was withdrawn shares dropped to below the pre-bid price.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,894.20 | 5.90 | 0.07% |
| CAC 40 | 8,076.45 | 1.84 | 0.02% |
| DAX 40 | 23,779.80 | 68.94 | 0.29% |
| Dow JONES (US) | 47,474.46 | 185.13 | 0.39% |
| FTSE 100 | 9,689.06 | 12.74 | -0.13% |
| HKSE | 25,760.73 | 334.32 | -1.28% |
| NASDAQ | 23,413.67 | 137.75 | 0.59% |
| Nikkei 225 | 49,864.68 | 561.23 | 1.14% |
| NZX 50 Index | 13,582.54 | 79.77 | 0.59% |
| S&P 500 | 6,829.37 | 16.74 | 0.25% |
| S&P/ASX 200 | 8,595.20 | 4.90 | 0.06% |
| SSE Composite Index | 3,878.00 | 19.71 | -0.51% |